{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Gleber-Netto FO"],"funding":["The University of Texas MD Anderson Cancer Center","NCATS NIH HHS","National Institutes of Health CTSA Program","National Cancer Institute","NCI NIH HHS"],"pagination":["124762"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6485353"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["4(1)"],"pubmed_abstract":["Incidence of HPV+ oropharyngeal squamous cell carcinoma (OPSCC) has been increasing dramatically. Although long-term survival rates for these patients are high, they often suffer from permanent radiotherapy-related morbidity. This has prompted the development of de-escalation clinical protocols to reduce morbidity. However, a subset of patients do not respond even to standard therapy and have poor outcomes. It is unclear how to properly identify and treat the high- and low-risk HPV+ OPSCC patients. Since HPV positivity drives radiotherapy sensitivity, we hypothesized that variations in HPV biology may cause differences in treatment response and outcome. By analyzing gene expression data, we identified variations in HPV-related molecules among HPV+ OPSCC. A subset of tumors presented a mole"],"journal":["JCI insight"],"pubmed_title":["Variations in HPV function are associated with survival in squamous cell carcinoma."],"pmcid":["PMC6485353"],"funding_grant_id":["P30CA016672","UL1TR001442","P30 CA016672","R50 CA211533","UL1 TR001442","HPV Moon Shot Program"],"pubmed_authors":["Kalu NN","Shen L","Gleber-Netto FO","Pickering CR","Xi Y","Rao X","Frederick MJ","Guo T","Erikson K","Myers JN","Xu G","Fisch KM","Wang J","Califano J","Seiwert T","Gao M","Skinner HD","Akagi K","Johnson FM","Ren S","Gillison M"],"additional_accession":[]},"is_claimable":false,"name":"Variations in HPV function are associated with survival in squamous cell carcinoma.","description":"Incidence of HPV+ oropharyngeal squamous cell carcinoma (OPSCC) has been increasing dramatically. Although long-term survival rates for these patients are high, they often suffer from permanent radiotherapy-related morbidity. This has prompted the development of de-escalation clinical protocols to reduce morbidity. However, a subset of patients do not respond even to standard therapy and have poor outcomes. It is unclear how to properly identify and treat the high- and low-risk HPV+ OPSCC patients. Since HPV positivity drives radiotherapy sensitivity, we hypothesized that variations in HPV biology may cause differences in treatment response and outcome. By analyzing gene expression data, we identified variations in HPV-related molecules among HPV+ OPSCC. A subset of tumors presented a mole","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Jan","modification":"2026-05-03T16:32:55.24Z","creation":"2019-06-06T22:49:41Z"},"accession":"S-EPMC6485353","cross_references":{"pubmed":["30626753"],"doi":["10.1172/jci.insight.124762"]}}